Unknown PHASE2 INTERVENTIONAL 1-arm NCT06074107

Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects

An Open, Multicenter Phase II Study of the Efficacy and Safety of BEBT-908 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Sponsor: BeBetter Med Inc

Conditions Relapsed or Refractory Diffuse Large B-cell Lymphoma

Interventions BEBT-908 for injection

Updated 4 times since 2023 Last updated: Oct 8, 2023 Started: Jun 12, 2020 Primary completion: Dec 20, 2023 Completion: Dec 25, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Relapsed or Refractory Diffuse Large B-cell Lymphoma, this trial is ongoing. The trial is conducted by BeBetter Med Inc and has accumulated 4 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Dec 2025 — Present [monthly]

Unknown PHASE2

Status: Active Not Recruiting → Unknown
Sep 2024 — Dec 2025 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Nov 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE2

First recorded

Jun 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BeBetter Med Inc

Data source: BeBetter Med Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China